Coronado Biosciences Announces Sale of Common Stock in Its at-the-Market Public Offering

BURLINGTON, Mass., April 11, 2013 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer, announced today that it has sold through its at-the-market program 1,000,000 shares of its common stock to Jennison Associates LLC (on behalf of fund clients) at yesterday's closing price of $10.12. MLV & Co., located in New York City, acted as the sales agent for the sale. The net proceeds to the Company from this at-the-market sale are approximately $9.9 million after deducting commissions.